Japan approves GSK’s Sotrovimab COVID-19 antibody treatment
2/2
© Reuters. FILE PHOTO: A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls
2/2
TOKYO (Reuters) – Japan has approved GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.
More Stories
Oil inches higher as Middle East tensions heat up
© Reuters. Army soldier miniatures and stock graph are seen in this illustration taken October 9, 2023. REUTERS/Dado Ruvic/Illustration/File Photo...
Asian stocks rise before US CPI; Japan’s Nikkei extends rally
. JP225 +1.88% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to: + Add another position...
SEC approves spot Bitcoin ETFs
. SEC approves spot bitcoin ETFs BTC/USD +1.76% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully...
Google lays off hundreds in Assistant, hardware, engineering teams
© Reuters. The Google logo is seen on the Google house at CES 2024, an annual consumer electronics trade show,...
US SEC approves bitcoin ETFs in watershed for crypto market
© Reuters. FILE PHOTO: FILE PHOTO: U.S. Securities and Exchange Commission logo and representations of cryptocurrency are seen in this...
Amazon has not offered remedies to EU concerns over iRobot deal
© Reuters. FILE PHOTO: The logo of Amazon is seen at the company's logistics centre in Boves, France, October 6,...